The session will provide an overview of FDA Diversity Action Plans and relevant implications for industry, equipping pharma and biotech professionals with essential knowledge and pragmatic guidance for navigating the evolving regulatory landscape.
Learning Objectives
Discuss key changes in recent guidance, impact on clinical trials, and trends for FDA Diversity Action Plans; Collect essential knowledge and pragmatic guidance to navigate the evolving regulatory landscape for Diversity Action Plans
Chair
Teresa Oblak, PhD
Tuesday June 17, 2025 12:20pm - 12:50pm EDT TBDWalter E. Washington Convention Center 801 Allen Y. Lew Place, NW Washington, DC 20001-3614 USA
